Overview
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2024-04-01
2024-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract SurgeryPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
EyePoint Pharmaceuticals, Inc.
Criteria
Inclusion Criteria:- Male or female subjects at least 40 years of age scheduled for cataract surgery
- Best corrected visual acuity (BCVA) of 20/30-20/200 in the study eye
- Must be considered by the investigator to have visual (VA) acuity potential greater
than 20/30 in the study eye.
Exclusion Criteria:
- Use of any corticosteroids within 7 days prior to Day 0
- Injection of any corticosteroids, systemic immunomodulators or alkylating agents into
any body tissue within 90 days
- Score greater than "0" on the Ocular Pain Assessment in the study eye at Screening.